Completed Heart Failure Clinical Trials

Listed below are recently completed heart failure clinical trials.  For currently enrolling studies, please go to the Heart Failure Clinical Trials page.

ATOMIC-AHF

A Double-Blind, Randomized, Placebo-Controlled, Multicenter STudy to Evaluate the Safety and Efficacy of IV Infusion Treatment with Omecamti Mecarbil in Subjects with Left Ventricular Systolic Dysfunction Hospitalzied for Acute Heart Failure

Purpose: To evaluate the effect of 48 hours of intravenous omecamtiv mecarbil complred with placebo on dyspnea in subjects with left bentricular systolic dysfunction hospitalized for acutre heart failure.

Note: Enrollment is closed.

AVOID-HF

Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure

Purpose: The purpose of the research is to determine if patients have fewer Heart Failure (HF) events after receiving Aquapheresis (AQ) therapy compared to intravenous (IV) diuretics up to 90 days of discharge from the hospital. Heart Failure events are defined as returning to the hospital, clinic or emergency department (ED) for treatment of HF symptoms.

Note:  Enrollment stopped prematurely by sposor.  

CHAMPION-CA

CHAMPION Continued Access: Cardio MEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients

Purpose: This study is being done to evaluate the safety and efficacy of the HF pressure measurement system in reducing heart failure related hospitalizations in patients suffering from heart failure.

Note: Enrollment is closed.  Subjects enrolled are participating in an additional 2 year follow up. The objective of the trial is to assess long-term safety for patients continuing to use the Champion TM HF Monitoring System. 

EXACT-HF

Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients

Purpose: The purpose of this study is to determine the benefits and safety of allopurinol, taken once or twice a day by mouth, in patients with heart failure and elevated blood uric acid levels.  The primary objective is to determine whther chronic inhibition of xanthine oxidase produces clinical benefits in hyperuricemic heart failure patients with left ventricular systolic dysfunction.

Note: Enrollment is closed.

IMPROVE-HF

Improve-HF Bridge Pilot Study

Purpose: The purpose of this study is to test a strategy of bridging the transition form inpatient to outpatient care with expert evaluation.  Secondly, it will evalutate a means of bridging the communication gap between specialty and primary care (transition of care).

Note: Enrollment is closed.

NEAT-HFpEF

Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction (NEAT)

Purpose: A randomized, double-blinded, placebo-controlled crossover study to assess effect of isosorbide mononitrate with dose up-titration on activity tolerance as assessed by (hip-worn, tri-axial) accelerometry.

Note: Enrollment is closed.

PRESERVE

Promotion of Renal Sodium Excretion by Renal Sympathetic Denervation in Congestive Heart Failure

PI: Javed Butler, MD

Purpose: Congestive heart failure is a common disorder in which the heart cannot pump enough blood to meet the needs of the rest of the body. Poor sodium handling by the kidneys is a damaging effect of heart failure, and it leads to symptoms of congestion such as shortness of breath or ankle swelling. Recent studies suggest that reducing the nerve activity to a kidney could reduce sodium retention and blood pressure. An improvement in the way the kidneys handle sodium may reduce disease progression and decrease symptoms for heart failure patients.

Note: Enrollment is closed.

ROSE-AHF

Renal Optimization Strategies Evaluation in Acute Heart Failure

Purpose: The purpose of this study is to determine the benefits and safety of intravenous administration of low dose nesiritide or low dose dopamine in patients with congestive heart failure and kidney dysfunction. There is a substudy in a subset of subjects that is being used to determine whether the Provocative Dyspnea Severity Score (pDSS) is a more sensitive index of variability in clinical status than the dyspnea VAS assessed without standardization of conditions at assessments.

Note: Enrollment is closed.